Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice

Cancer Research

Volumn 72, Issue 8, 2012, Pages 2089-2099

  Hurez, Vincent ^a   Daniel, Benjamin J ^a   Sun, Lishi ^a   Liu, Ai Jie ^a   Ludwig, Sara M ^a   Kious, Mark J ^a   Thibodeaux, Suzanne R ^a   Pandeswara, Srilakshmi ^a   Murthy, Kruthi ^a   Livi, Carolina B ^a   Wall, Shawna ^a   Brumlik, Michael J ^a   Shin, Tahiro ^a   Zhang, Bin ^a   Curiel, Tyler J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; FLUOROURACIL; GR1 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AGE; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOCOMPETENCE; IMMUNOPATHOLOGY; IN VITRO STUDY; JUVENILE ANIMAL; MELANOMA; MONOTHERAPY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T CELL DEPLETION; TUMOR GROWTH; TUMOR IMMUNITY;

AGING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84860181087     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3019     Document Type: Article

References (38)

1. Feng Z, Hu W, Rajagopal G, Levine AJ. The tumor suppressor p53: cancer and aging. Cell Cycle 2008;7:842-7. (Pubitemid 351573774)
2. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med 2011;11:537-50.
3. Vallejo AN. Immunological hurdles of ageing: indispensable research of the human model. Ageing Res Rev 2011;10:315-8.
4. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 2004;172:5194-9. (Pubitemid 38542015)
5. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74. (Pubitemid 46718401)
6. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241-6.
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
8. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
9. Zhang H, Podojil JR, Luo X, Miller SD. Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis. J Immunol 2008;181:4638-47.
10. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007;188: 117-27. (Pubitemid 47095016)
11. + regulatory T cells in aged Balb/c mice. J Leukoc Biol 2007;81:1386-94.
12. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Research 2009;69:3995-4000.
13. Kozlowska E, Biernacka M, Ciechomska M, Drela N. Age-related changes in the occurrence and characteristics of thymic CD4(+) CD25(+) T cells in mice. Immunology 2007;122:445-53. (Pubitemid 47556482)
14. Thomas DC, Mellanby RJ, Phillips JM, Cooke A. An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice. Immunology 2007;121:565-76. (Pubitemid 47030094)
15. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182: 4499-506.
16. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009;182:240-9.
17. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.
18. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79. (Pubitemid 351430364)
19. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res 2006;66:1123-31.
20. Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res 2008;68:5423-31.
21. Sharma S, Dominguez AL, Lustgarten J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 2006;177:8348-55. (Pubitemid 44893796)
22. Grizzle WE, Xu X, Zhang S, Stockard CR, Liu C, Yu S, et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 2007;128:672-80. (Pubitemid 350299050)
23. Enioutina EY, Bareyan D, Daynes RA. A role for immature myeloid cells in immune senescence. J Immunol 2011;186:697-707.
24. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007;445:766-70. (Pubitemid 46279706)
25. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8:191-7. (Pubitemid 46152650)
26. Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 2010;185:2747-53.
27. Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, et al. Aging-associated B7-DC(+) B cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell 2012;11:128-38.
28. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7. (Pubitemid 36597102)
29. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007;110:3192-201. (Pubitemid 350106311)
30. Ouyang X, Yang Z, Zhang R, Arnaboldi P, Lu G, Li Q, et al. Potentiation of Th17 cytokines in aging process contributes to the development of colitis. Cell Immunol 2011;266:208-17.
31. Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J Immunol 2006;176:6586-93.
32. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
33. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 2009;58:1979-89.
34. Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P, et al. Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol 2009;183:7631-4.
35. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associatedmyeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61.
36. Ruby CE, Weinberg AD. OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 2009;182:1481-9.
37. Lustgarten J, Dominguez AL, Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 2004;173:4510-5. (Pubitemid 39280681)
38. Bansal-Pakala P, Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol 2002;169:5005-9. (Pubitemid 35217168)